anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients undergoing elective Total knee arthroplasty (TKA) by surgeons from NYU Langone with the presence of a pre-operative knee flexion contracture greater than 5 degrees and willingness to participate in our institution's outpatient rehabilitation and physical therapy. Those randomized to this group will be fitted with a Guardian Rehabilitator Brace.
OBJECTIVE: Research indicates that perceived injustice significantly influences pain-related outcomes and is associated with delayed recovery in adults. This systematic review examines the relationship between perceived injustice and pain-related outcomes in children with pain conditions.
METHODS: A search of published studies in English in PubMed, PsychInfo, and Cochrane Database of Systematic Reviews from database inception through December 2022 were performed. The search criteria focused on studies that measured perceived injustice and pain-related outcomes in children with pain conditions. Out of 56 articles screened, 8 met the inclusion criteria, providing data on 1240 children with pain conditions.
RESULTS: The average age of participants across all studies was 14.12 years (SD = 2.25), with 68.2% being female. There was strong evidence that higher perceived injustice is associated with worse pain intensity, functional disability, mental health outcomes, and emotional, social, and school functioning.
CONCLUSION: The results of this study underscore how perceptions of injustice are associated various pain-related outcomes across different domains of children's lives. The findings highlight the need for screening and treatments targeting injustice appraisals in pediatric populations with pain conditions. The discussion addresses possible determinants and mechanisms of perceived injustice, along with implications for research and clinical practice.
The effect of drought stress on leaf physiology was studied in 10-month-old plants of Sindora siamensis . Plants were either placed in an open greenhouse (unhardening; UH) or in an open field (open field hardening; H) for 45days. Both the UH and H plants stopped receiving water (D) until the initial drought injury and then rewatered (R) until complete recovery. Results showed necrosis in the leaves of UH+D, while H+D showed wilting at Day 7 after drought. A greater degree of necrosis was found in UH+D+R but made complete recovery in H+D+R at Day 4 after rewatering. Drought stress resulted in decreased leaf area in H, and reduced leaf and stem water status, PSII efficiency, net photosynthetic rate, stomatal conductance and transpiration rate in both UH and H. It also resulted in an increase in water use efficiency in both UH and H. Electrolyte leakage and malondialdehyde contents in UH were markedly increased due to drought stress. These results suggest that unhardened young plants of Sindora exposed to drought exhibited enhanced stomata behaviour by minimising open stomata and transpiration, resulting in high efficiency of water usage. However, there was still membrane damage from lipid peroxidation, which caused necrosis. Open field hardened plants exposed to drought demonstrated reduced open stomata and transpiration, thereby preserving leaf and soil water status and enhancing water use efficiency. This may be a reduction in lipid peroxidation though an oxidative scavenging mechanism that causes a slight alteration in membrane stability and a slight necrosis.
Materials and apparatus are provided that exhibit increased efficiency. The apparatus includes an antiperspirant composition with a citric acid stain reducing agent. The antiperspirant composition includes a water-in-oil emulsion. The water-in-oil emulsion includes an oil-phase component disposed within the water-in-oil emulsion. The water-in-oil emulsion includes a water-phase component disposed within the water-in-oil emulsion. The water-phase component includes an active antiperspirant ingredient. The water-phase component also includes a citric acid stain reducing agent forming between 0.1 to 8.0 weight percent of the water-in-oil emulsion.
"Salt therapy," known as halotherapy, is a treatment method performed in salt chambers lined with salt crystals that are pumped with salt-laden air and is used to combat respiratory diseases, skin conditions, mental fatigue and stress. The word Halos means salt in Greek. This practice is also performed in naturally occurring salt mines or caves in Eastern European countries, which is called "speleotherapy" or "cave salt therapy".

Salt has been used for thousands of years in different parts of the world due to its therapeutic effect, and was first applied for therapeutic purposes by Polish Feliks Bockowski. Although salt mine workers in Poland lack basic needs such as nutrition and have difficult working conditions, their general health has led researchers to study and observe in the salt field. In this observation, it was determined that mine workers were less likely to catch colds or any respiratory system diseases. Salt mines were thought to have health benefits, and salt caves in Eastern Europe and Poland became popular.

The research was planned as an experimental study with experimental and control groups. Participants to be included in the study will be children between the ages of 4-10, diagnosed with asthma and without any other chronic diseases, who volunteer to participate. "Personal Information Form", "SPO2 measurements", "Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form" and "Informed Voluntary Consent Form" will be used to collect data. The sample of the research was calculated using the GPower computer program. With power analysis, t-test in independent groups with a large effect size at α = 0.05 (d = 0.8) and in the calculation made to have a power of 95% of the study, it was found that a total of 70 children, 35 children in the control group and experimental groups, should be included. . "Personal Information Form", SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form" will be applied to the children in the experimental group before they are taken to the salt therapy room. The same procedure will be applied to the children in the control group. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week.
PURPOSE:To produce a cDNA derived from dengue virus 3 type, by screening a specific transformant to form a transformant containing a dengue virus 3 type cDNA and cultivating the resultant cDNA. CONSTITUTION:Cultivated cells, e.g. cell strain derived from Aedes albopictus Skuse, etc., are infected with dengue virus 3 type and cultivated to multiply the virus, which is then purified RNA is extracted from the purified virus with phenol to give an RNA derived from the virus. The resultant RNA is reacted with dATP, etc., in the presence of a reverse transcriptase to synthesize the corresponding cDNA. RNA is used as a template to prepare a cDNA labeled with a radioisotope and transformants are screened with the obtained cDNA as a probe to afford a dengue virus 3 type cDNA-containing transformant, which is then cultivated to multiply the cDNA. Thereby extraction with phenol, etc., is carried out to provide the aimed cDNA.
Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
PURPOSE: To obtain a pharmaceutical preparation useful for oral administration in a fluid form by formulating a biologically effective substance such as a psychopharmaceutical compound with a cellulosic derivative soluble in water and an organic solvent, a water-insoluble polymer and a filler in a specific proportion. CONSTITUTION: This composition for oral administration is obtained by formulating 1-5 pts.wt. biologically effective substance represented by the formula (X is C or N; Y is N and may be C when X is C; R1 is H, OH or an O-alkyl; R2 is H, OH, an O-alkyl, an alkyl or a halogen; R3 is H or an alkyl; the broken line is an addition bond which is, as necessary, present when Y is C), especially mianserin or mirtazepine with 0.3-3 pts.wt. cellulosic derivative soluble in water and an organic solvent, 4-20 pts.wt. water-insoluble pharmaceutically permissible polymer and 40-250 pts.wt. usually used filler. The composition is in a fluid form or a readily convertible into the fluid form. The composition is relatively tasteless and is easily orally administered without local anesthetic actions.
Patients treated with AVONEX and their caregivers should be advised to report immediately any symptoms of depression, suicidal ideation, and/or psychosis to their prescribing physicians. If a patient develops depression or other severe psychiatric symptoms, cessation of AVONEX therapy should be considered. 

Depression and suicide have been reported to occur with increased frequency in patients receiving AVONEX. In Study 1, the incidence of depression was similar in placebo-treated and in AVONEX-treated patients, but suicidal tendency was seen more frequently in AVONEX-treated patients (4% in AVONEX group vs. 1% in placebo group). In Study 2, there was a greater incidence of depression in AVONEX-treated patients than in placebo-treated patients (20% in AVONEX group vs. 13% in placebo group) [see Clinical Studies (14)]. 

Additionally, there have been postmarketing reports of depression, suicidal ideation, and/or development of new or worsening of other pre-existing psychiatric disorders, including psychosis. For some of these patients, symptoms of depression improved upon cessation of AVONEX.
The present invention administers a cannabinoid medication to a patient followed by observing one or more physiological responses in the patient during a first period of time when treating a medical condition. The cannabinoid medication may include one or more specific types of cannabinoids at an initial dosage level. In certain instances the cannabinoid dosage level in incremented over the first period of time. The dose of a cannabinoid corresponds to a mass of one or more cannabinoid types administered to the patient over a period of time, typically over a day. The cannabinoid treatment may be combined with one or more other methods for treating cancer, such as administering a chemotherapy agent, a KRAS inhibitor, or a CTLA-4 antigen. The present invention also includes a formulation of cannabinoid medications that span one or more ranges of milligram dosages of one or more cannabinoids in a set of formulary drugs.
PURPOSE: An AMP-activated protein kinase fusion protein is provided to suppress inflammation by intracellular concentration-dependent and time-dependent introduction. CONSTITUTION: A cell permeable AMP-activated protein kinase fusion protein has a protein transport domain which is bound to at least one terminal of the AMP-activated protein kinase. The protein transport domain is PEP-1 peptide. The AMP-activated protein kinase has an amino acid of sequence number 7. A cosmetic composition contains the AMP-activated protein kinase as an active ingredient. A pharmaceutical composition for treating inflammation including type 2 diabetes, obesity, skin cancer, and atopic inflammation contains the AMP-activated protein kinase as an active ingredient and pharmaceutically acceptable carrier.
Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism teams show great promise to improve management and outcomes of acute pulmonary embolism (PE). However, the absence of randomized evidence and lack of consensus leads to tremendous variations in treatment and compromises the wide implementation of new innovations. Moreover, the changing landscape of health care, where quality, cost, and accountability are increasingly relevant, dictates that a broad spectrum of outcomes of care must be routinely monitored to fully capture the impact of modern PE treatment. We set out to standardize data collection in patients with PE undergoing evaluation and treatment, and thus establish the foundation for an expanding evidence base that will address gaps in evidence and inform future care for acute PE. To do so, >100 international PE thought leaders convened in Washington, DC, in April 2022 to form the Pulmonary Embolism Research Collaborative. Participants included physician experts, key members of the US Food and Drug Administration, patient representatives, and industry leaders. Recognizing the multidisciplinary nature of PE care, the Pulmonary Embolism Research Collaborative was created with representative experts from stakeholder medical subspecialties, including cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery, emergency medicine, hospital medicine, and pharmacology. A list of critical evidence gaps was composed with a matching comprehensive set of standardized data elements; these data points will provide a foundation for productive research, knowledge enhancement, and advancement of clinical care within the field of acute PE, and contribute to answering urgent unmet needs in PE management. Evidence produced through the Pulmonary Embolism Research Collaborative, as it is applied to data collection, promises to provide crucial knowledge that will ultimately produce a robust evidence base that will lead to standardization and harmonization of PE management and improved outcomes.
The invention discloses a traditional Chinese medical decoction for treatment of chronic kidney diseases. According to the theory of traditional Chinese medicine, the chronic kidney diseases are caused by end-stage renal insufficiency, clinical manifestations include water, electrolytes, acid-base imbalance and a series of systemic poisoning symptoms resulting caused by storage of toxins. Traditional Chinese herbs with the effects of invigorating the spleen, tonifying kidney, clearing away heat and toxic materials, promoting blood circulation, excreting pathogenic water, and relieving swelling and pains are selected, including akebiaquinata, antenoron roots, fructus forsythiae, scutellaria baicalensis, common andrographis herbs, cordate houttuynia, radix rehmanniae, olibanum, rhizoma corydalis, semen coicis, cortex albiziae, salvia miltiorrhiza, rhizoma atractylodis alba, licorice, radix dipsaci, semen euryales and yam. The materials are brewed into the decoction to be taken by patients. The total efficiency is 90.3 percent which is significantly higher than the total efficiency of a control group. Kidney function parameters can be significantly improved. Moreover, the cost of treatment is low, no side effects can be caused, and the decoction is worth promoting.
The invention belongs to the fields of molecular biology and clinical medicine, and relates to a nucleic acid aptamer targeting IGF-1R and application thereof. The nucleic acid aptamer for targeting IGF-1R comprises any one nucleotide shown as SEQ ID NO. 1-SEQ ID NO. 3; or any one of derivatives of nucleic acid aptamer with the same function obtained by chemical modification, chemical marking or base change on the basis of SEQ ID NO. 1-SEQ ID NO. 3. The aptamer of the invention can be synthesized in vitro in large quantity, has low price, good stability and high affinity, is convenient to store and easy to edit; meanwhile, because the molecular weight is small, immune reaction is not easy to occur, the chemical stability of single-stranded DNA is good, the denaturation and renaturation are reversible, and the long-term storage and the transportation at room temperature are easy.
Aging of the skin is characterized by wrinkling, sagging, and laxity. About 80% of facial skin aging is classified as extrinsic, or photoaging because it results from exposure to UV light of the sun that causes oxidative stress The remaining 20% of facial aging is the intrinsic type which is partially caused by the accumulation of proteins that are modified by reactive carbonyls in a reaction known as protein glycation. Aging also shifts the composition of the gut microbiome in at least 35 genera towards an unhealthy state of dysbiosis.

Previous studies showed that muscadine polyphenols inhibited protein glycation under a simulated physiological condition. Additional experiments using cell culture and mice showed that dealcoholized muscadine wine alleviated inflammation and protected against dysbiosis in the gut. The objective of this research is to confirm the health benefits of muscadine wine polyphenols in a clinical trial. The investigators hypothesize that dealcoholized muscadine wine consumption in women 40-65 years old will alleviate skin photoaging and skin conditions by decreasing oxidative stress and inflammation. It is also expected to improve the composition of the gut microbiome.
The invention relates to methods and products for the preparation of antigen presenting cells, and for the modulation of T cell activation, for example to prepare activated T cells. The invention further relates to antigen presenting cells and activated T cells thus prepared. The invention further relates to methods and uses of such antigen presenting cells for activation of T cells in vitro, ex vivo; or in vivo, for treatment of e.g. a condition associated with immuno impairment, or for vaccination. The invention further relates to methods and uses of such activated T cells for treatment of e.g. a condition associated with immuno impairment.
In addition to the standard resection technique, the surgical procedure will include the application of AM with surgical adhesive at the surgical site. Following this, limbal cells will be harvested from the limbus in a resection measuring 2×2 mm, divided into six fragments, and positioned along the limbus border on the AM.
PROBLEM TO BE SOLVED: To obtain a new compound useful for, e.g. treatment of seasonal emotional disturbance, dysgryphia, cardiovascular disease, asomnia and fatigue resulting from jet lag, anorexia, and adiposis. SOLUTION: This compound is shown by formula I [A and B rings, when combined with each other, forms (1,2-dihydro)naphthalene, tetrahydronaphthalene or the like; T is a 1-6C alkylene chain which may be substituted by a 1-6C alkyl, OH or the like; R is H, OH or the like; G1 is COOH, formyl, cyano or the like; and G2 is shown by formula II (X is O or S; R2 is H or a 1-6C alkyl; R21 is a (substituted) 1-6C alkyl, (substituted) heteroaryl or the like) or the like] (enantiomer, diastereoisomer or addition salt) e.g. N-[2-(7-methoxy-3- phenyl-1-naphthyl)ethyl]acetamide. The compound shown by formula I can be obtained by, e.g. reacting a compound shown by formula III (G3 is COOH or NH-R2 ) with a compound shown by formula IV to produce a compound shown by formula V, and reacting the product compound with a sulfiding reagent.
To explore the therapeutic effect of traditional Chinese medicine (TCM) nursing technology combined with TCM massage on elderly patients with functional constipation (FC). Ninety elderly patients with FC admitted to our hospital from January 2022 to February 2023 were selected and randomly divided into 3 groups. The control group was treated with conventional Western medicine, observation group 1 was treated with TCM massage on the basis of the control group, and observation group 2 was treated with medicine ironing combined with TCM massage on the basis of the control group. Compare 3 groups of TCM syndrome scores, clinical efficacy, complete spontaneous bowel movements (CSBM) per week, Bristol fecal trait scale, and safety. There was a statistically significant difference in clinical effective rates among the 3 groups (96.67%, 83.33%, 66.67%) (P < .05), and the observation group 2 was higher than the observation group 1 and higher than the control group. After treatment, the TCM syndrome scores of the 2 groups were lower than those of the observation group 1 and the control group; And observation showed that the TCM syndrome score of group 1 was lower than that of the control group (P < .05). After treatment, the increase in scores of CSBM and Bristol fecal traits in the 2 groups was higher than that in the observation group and control group, and the increase in scores of CSBM and Bristol fecal traits in the observation group was higher than that in the control group (P < .05). There was no statistically significant difference in the incidence of adverse reactions among the 3 groups (10.00%, 6.67%, 20.00%) (P > .05). The application of TCM nursing techniques such as TCM ironing and TCM massage in elderly patients with FC has a significant clinical effect, which can effectively improve clinical symptoms, defecation frequency, and fecal characteristics, and has high safety.
Novel therapeutics for the treatment of ischemic stroke remains to be the unmet clinical needs. Previous studies have indicated that salvianolic acid A (SAA) is a promising candidate for the treatment of the brain diseases. However, SAA has poor absolute bioavailability and does not efficiently cross the intact blood-brain barrier (BBB), which limit its efficacy. To this end we developed a brain-targeted liposomes for transporting SAA via the BBB by incorporating the liposomes to a transport receptor, insulin-like growth factor-1 receptor (IGF1R). The liposomes were prepared by ammonium sulfate gradients loading method. The prepared SAA-loaded liposomes (Lipo/SAA) were modified with IGF1R monoclonal antibody to generate IGF1R antibody-conjugated Lipo/SAA (IGF1R-targeted Lipo/SAA). The penetration of IGF1R-targeted Lipo/SAA into the brain was confirmed by labeling with Texas Red, and their efficacy were evaluate using middle cerebral artery occlusion (MCAO) model. The results showed that IGF1R-targeted Lipo/SAA are capable of transporting SAA across the BBB into the brain, accumulation in brain tissue, and sustained releasing SAA for several hours. Administration o IGF1R-targeted Lipo/SAA notably reduced infarct size and neuronal damage, improved neurological function and inhibited cerebral inflammation, which had much higher efficiency than no-targeted SAA.
Intensity modulated radiotherapy (IMRT) combined with high-dose cisplatin is the standard treatment for locally advanced head and neck squamous cell carcinoma. Previous clinical studies of concurrent chemoradiotherapy have shown that the incidence of nausea and vomiting after treatment with 5-HT3RA and dexamethasone is about 40%. Nausea and vomiting seriously affect the patient's treatment tolerance and quality of life. In our previous prospective phase 2 study (NCT03572829), the triple antiemetic regimen of NK-1R antagonist (aprepitant), dexamethasone and ondansetron was firstly used in patients with head and neck squamous cell carcinoma who received concurrent chemoradiotherapy. the primary endpoint-complete response rate was 86%, and the incidence of no vomiting was 88.4%, which was better than the data previously reported in the literatures. The incidence of no nausea was only 60.5%, and the hiccup caused by dexamethasone was as high as 16%. And with the confirmation of the efficacy of immunotherapy in head and neck squamous cell carcinoma, the use of dexamethasone may reduce immunotherapy. Therefore, it is necessary to further optimize the antiemetic regimen. In recent years, a number of randomized studies have confirmed that the addition of olanzapine can reduce the incidence of nausea and increase the complete response rate of high emetic chemotherapy. Other randomized studies have shown that in patients with malignant tumors (including head and neck squamous cell carcinoma and esophageal cancer) receiving concurrent chemoradiotherapy, the NK-1R antagonist was changed to olanzapine on the basis of the original triple regimen, which significantly redeced the incidence of nausea.

Therefore, on the basis of previous studies, this study intends to conduct a prospective, single-arm phase II study to explore the efficacy and safety of olanzapine combined with aprepitant and palonosetron in the prevention of nausea and vomiting in patients with locally advanced head and neck squamous cell carcinoma receiving IMRT and concurrent chemotherapy..